Search
Close this search box.

Clinical report: getting behind Verve’s PCSK9 Phase I safety signal  

ARTICLE | Product Development

Plus readouts from Gritstone, Disc, BMS and Novocure

By Lauren Martz, Executive Director, Biopharma Intelligence

April 3, 2024 12:31 AM UTC

Delivery is still one of the greatest challenges for genetic therapies, and a decision by Verve Therapeutics Inc. (NASDAQ:VERV) to deprioritize its lead base editor proves that even delivery to the liver hasn’t been perfected.

On Tuesday, Verve announced it had paused enrollment in the Phase Ib Heart-1 trial of lead program VERVE-101 after one of six patients with heterozygous familial hypercholesterolemia treated at the 0.45 mg/kg dose experienced a pair of Grade 3 adverse events — liver toxicity and thrombocytopenia…